Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 275 Show results per page	View Search Criteria \| Help With Results


1.		An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Treatment				Active				18 and over				Pharmaceutical / Industry				U2963n NCT00097565


2.		Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				12 to 55				Pharmaceutical / Industry				GC P#02.01.001 NCT00469729

Last Modified: 6/9/2008 First Published: 9/26/2007


3.		Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 and over				NCI				RPCI-I-72806 I 72806, NCT00536601


4.		In-Vivo Activated T-Cell Depletion to Prevent GVHD

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				18 to 75				Other				0705-20 IUCRO-0196 NCT00594308


5.		Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 to 70				Other				F080429003 UAB-0775, NCT00714259

Last Modified: 8/21/2008 First Published: 12/22/2004


6.		Phase III Randomized Study of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Single Agent Therapy in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UCLA-0406049-01 CTI-PIX301, NCT00101049


7.		Mobilization of Stem Cells with AMD3100 in Non-Hodgkin’s Lymphoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 78				Pharmaceutical / Industry				AMD3100-3101 NCT00103610

Last Modified: 10/24/2008 First Published: 6/25/2005


8.		Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-50303 CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209


9.		PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				9823 H6Q-MC-JCBJ, PRELUDE, NCT00332202


10.		Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 80				NHLBI				384 BMT CTN 0401, U01 HL069294-05, NCT00329030

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute